Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2015

01-08-2015 | Epidemiology

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer

Authors: A. Jo Chien, Erin Duralde, Richard Hwang, Karen Tsung, Chia-Ning Kao, Hope S. Rugo, Michelle E. Melisko, Laura J. Esserman, Pamela N. Munster, Marcelle Cedars, Karla Kerlikowske, Charles E. McCulloch, Mitch P. Rosen

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Login to get access

Abstract

The impact of long-term tamoxifen therapy on ovarian function is not known. Understanding these effects will help reproductive-aged patients who desire future pregnancy make more informed decisions regarding their treatment. This is a retrospective cohort study in patients identified through the UCSF Cancer Registry and SPORE database. We enrolled women with a history of ductal carcinoma in situ (DCIS) or early stage invasive breast cancer who were premenopausal at diagnosis and did not receive chemotherapy. Menstrual histories were obtained through electronic and paper surveys. We compared the age of menopause onset and menstrual pattern changes between women who received tamoxifen (TAM) and those who did not receive tamoxifen (control). Neither group received chemotherapy. 250 subjects were included in this study (125 TAM, 125 control). Mean age of menopause onset was 51.0 for both the groups and was not associated with duration of tamoxifen use or the age at tamoxifen initiation. Menstrual pattern changes, including amenorrhea, were more frequent in the TAM group than control group (any change: 48 % TAM vs. 15 % control, p < 0.001; amenorrhea: 22 % TAM vs. 3 % control, p < 0.001). Older age was associated with an increased risk of developing amenorrhea within 6 months of starting tamoxifen (HR 1.32, p < 0.001). Menstrual pattern changes are common in premenopausal women taking tamoxifen. Tamoxifen use in the absence of chemotherapy is not associated with an earlier age onset of menopause in patients with DCIS or invasive breast cancer and is unlikely to significantly accelerate ovarian aging.
Literature
1.
2.
3.
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC (2009) Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 7(2):122–192PubMed
4.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005). Lancet 365 (9472):1687–1717
5.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652–1662. doi:10.​1093/​jnci/​dji372 CrossRefPubMed
6.
Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N (2001) Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28(4):400–418CrossRefPubMed
7.
Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24(7):1045–1051CrossRefPubMed
8.
Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365–2370PubMed
9.
Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14(5):1718–1729PubMed
10.
Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R (2007) The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 30(2):126–132CrossRefPubMed
11.
Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671–1676. doi:10.​1200/​JCO.​2008.​20.​2119 CrossRefPubMed
12.
Rowe T (2006) Fertility and a woman’s age. J Reprod Med 51(3):157–163PubMed
13.
te Velde ER, Pearson PL (2002) The variability of female reproductive ageing. Hum Reprod Update 8(2):141–154CrossRef
14.
15.
Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA (2009) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113(2):315–320. doi:10.​1007/​s10549-008-9937-0 CrossRefPubMed
16.
17.
Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P, Santi L et al (1990) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. J Clin Oncol 8(8):1310–1320PubMed
18.
Manni A, Pearson OH (1980) Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64(6–7):779–785PubMed
19.
Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC (1991) Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83(20):1488–1491CrossRefPubMed
20.
Jordan VC, Fritz NF, Tormey DC (1987) Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47(2):624–630PubMed
21.
22.
Swahn ML, Bygdeman M, Matlin SA, Wu ZY (1989) The effect of tamoxifen on the function and lifespan of the corpus luteum and on subsequent ovarian function. Acta Endocrinol 121(3):417–425PubMed
23.
International Breast Cancer Study G, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD (2006) Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international Breast Cancer Study Group Trial 13–93. J Clin Oncol 24(9):1332–1341. doi:10.​1200/​JCO.​2005.​03.​0783 CrossRef
24.
Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA (2013) Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation. J Clin Oncol 31(31):3914–3919. doi:10.​1200/​JCO.​2012.​47.​7893 PubMedCentralCrossRefPubMed
25.
26.
27.
28.
Lin WT, Beattie M, Chen LM, Oktay K, Crawford SL, Gold EB, Cedars M, Rosen M (2013) Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 119(9):1652–1659. doi:10.​1002/​cncr.​27952 PubMedCentralCrossRefPubMed
29.
30.
Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S (2014) Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations. J Clin Oncol 32(10):1093–1094. doi:10.​1200/​JCO.​2013.​53.​5369 CrossRefPubMed
31.
Colditz GA, Stampfer MJ, Willett WC, Stason WB, Rosner B, Hennekens CH, Speizer FE (1987) Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 126(2):319–325CrossRefPubMed
32.
33.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R, Adjuvant Tamoxifen: Longer Against Shorter Collaborative G (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816. doi:10.​1016/​S0140-6736(12)61963-1 PubMedCentralCrossRefPubMed
34.
Metadata
Title
Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer
Authors
A. Jo Chien
Erin Duralde
Richard Hwang
Karen Tsung
Chia-Ning Kao
Hope S. Rugo
Michelle E. Melisko
Laura J. Esserman
Pamela N. Munster
Marcelle Cedars
Karla Kerlikowske
Charles E. McCulloch
Mitch P. Rosen
Publication date
01-08-2015
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-015-3511-3

Other articles of this Issue 1/2015

Breast Cancer Research and Treatment 1/2015 Go to the issue

Clinical trial

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy

Preclinical study

Chronic oxidative stress causes estrogen-independent aggressive phenotype, and epigenetic inactivation of estrogen receptor alpha in MCF-7 breast cancer cells

Preclinical Study

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

Review

Post-irradiation angiosarcoma of the breast: clinical presentation and outcome in a series of six cases

Clinical trial

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure

Editorial

Guidelines are essential to improving clinical outcomes in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits